Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services?
Abstract
:1. Introduction
1.1. Background
1.2. Community Pharmacists and Pharmacogenomic Testing
2. Materials and Methods
2.1. Study Design
2.2. Sample Size and Participants
2.3. Ethics
2.4. Pilot and Data Collection
2.5. Data Analysis
3. Results
3.1. Demographic Information
3.2. Awareness and Training
3.3. General Views and Experience
3.4. Barriers to PG Implementations
3.5. Willingness and Confidence
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Fadason, T.; Farrow, S.; Gokuladhas, S.; Golovina, E.; Nyaga, D.; O’Sullivan, J.M.; Schierding, W. Assigning Function to SNPs: Considerations When Interpreting Genetic Variation. Semin. Cell Dev. Biol. 2022, 121, 135–142. [Google Scholar] [CrossRef] [PubMed]
- Lencz, T.; Darvasi, A. Single Nucleotide Polymorphisms (SNPs). In Reference Module in Life Sciences; Elsevier: Amsterdam, The Netherlands, 2017. [Google Scholar] [CrossRef]
- Orrico, K.B. Basic Concepts in Genetics and Pharmacogenomics for Pharmacists. Drug Target Insights 2019, 13, 117739281988687. [Google Scholar] [CrossRef]
- Nakatani, K.; Nobori, T. Pharmacogenomics. Jpn. J. Clin. Pathol. 2013, 6, 1018–1025. [Google Scholar]
- Lopez, D. Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. Int. J. Biomed. Investig. 2018, 1, 1–16. [Google Scholar] [CrossRef] [PubMed]
- Royal College of Physicians and British Pharmacological Society Roport. In Personalised Prescribing, Using Pharmacogenomics to Improve Patient Outcomes; Report of a Working Party; RCP and BPS; British Pharmacological Society: London, UK, 2022.
- Ma, J.D.; Lee, K.C.; Kuo, G.M. HLA-B*5701 Testing to Predict Abacavir Hypersensitivity. PLoS Curr. 2010, 2, RRN1203. [Google Scholar] [CrossRef]
- Brown, S.-A.; Pereira, N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. J. Pers. Med. 2018, 8, 8. [Google Scholar] [CrossRef]
- Lee, C.R.; Luzum, J.A.; Sangkuhl, K.; Gammal, R.S.; Sabatine, M.S.; Stein, C.M.; Kisor, D.F.; Limdi, N.A.; Lee, Y.M.; Scott, S.A.; et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin. Pharmacol. Ther. 2022, 112, 959–967. [Google Scholar] [CrossRef]
- National Institute for Health and Care Excellence (NICE). Clopidogrel Genotype Testing after Ischaemic Stroke or Transient Ischaemic Attack (Draft). Available online: https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents (accessed on 13 September 2023).
- Rendell, T.; Barnett, J.; Wright, D. Co-Designing a Community Pharmacy Pharmacogenomics Testing Service in the UK. BMC Health Serv. Res. 2022, 22, 378. [Google Scholar] [CrossRef]
- Alexander, K.M.; Divine, H.S.; Hanna, C.R.; Gokun, Y.; Freeman, P.R. Implementation of Personalized Medicine Services in Community Pharmacies: Perceptions of Independent Community Pharmacists. J. Am. Pharm. Assoc. 2014, 54, 510–517. [Google Scholar] [CrossRef]
- Berenbrok, L.A.; Hart, K.M.; McGrath, S.H.; Coley, K.C.; Somma McGivney, M.A.; Empey, P.E. Community Pharmacists’ Educational Needs for Implementing Clinical Pharmacogenomic Services. J. Am. Pharm. Assoc. 2019, 59, 539–544. [Google Scholar] [CrossRef]
- Papastergiou, J.; Tolios, P.; Li, W.; Li, J. The Innovative Canadian Pharmacogenomic Screening Initiative in Community Pharmacy (ICANPIC) Study. J. Am. Pharm. Assoc. 2017, 57, 624–629. [Google Scholar] [CrossRef] [PubMed]
- Connelly, D. Pharmacogenomic Testing Pilot to Start in General Practice from June 2023. Pharm. J. 2023, 310, 7973. [Google Scholar] [CrossRef] [PubMed]
- Swen, J.J.; van der Wouden, C.H.; Manson, L.E.N.; Abdullah-Koolmees, H.; Blagec, K.; Blagus, T.; Böhringer, S.; Cambon-Thomsen, A.; Cecchin, E.; Cheung, K.-C.; et al. A 12-Gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions: An Open-Label, Multicentre, Controlled, Cluster-Randomised Crossover Implementation Study. Lancet 2023, 401, 347–356. [Google Scholar] [CrossRef] [PubMed]
- NHS England. NHS Genomic Medicine Service. Available online: https://www.england.nhs.uk/genomics/nhs-genomic-med-service/ (accessed on 17 October 2023).
- Royal Pharmaceutical Society. The Future of Pharmacy in a Sustainable NHS. Available online: https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Future%20of%20Pharmacy/Future%20of%20Pharmacy%20Policy%20Asks%20Summary.pdf (accessed on 17 October 2023).
- Raosoft. Raosoft Sample Size Calculator [Internet]. Available online: http://www.raosoft.com/samplesize.html (accessed on 10 March 2023).
- Jarrar, Y.; Musleh, R.; Ghanim, M.; AbuKhader, I.; Jarrar, Q. Assessment of the Need for Pharmacogenomics Education among Pharmacists in the West Bank of Palestine. Int. J. Clin. Pract. 2021, 75, e14435. [Google Scholar] [CrossRef] [PubMed]
- Mehtar, M.; Hammoud, S.H.; Amin, M.E.K. An Objective Evaluation of Fundamental Pharmacogenomics Knowledge among Pharmacists and Pharmacy Students. Saudi Pharm. J. 2022, 30, 1765–1772. [Google Scholar] [CrossRef]
- Venugopal, M.-L.; Yong, F.R.; Krzyzaniak, N.; La Caze, A.; Freeman, C. Mapping Australian Pharmacy School Curricula for Content Related to Pharmacogenomics. Explor. Res. Clin. Soc. Pharm. 2022, 8, 100192. [Google Scholar] [CrossRef]
- Doellner, J.F.; Dettloff, R.W.; DeVuyst-Miller, S.; Wenstrom, K.L. Prescriber Acceptance Rate of Pharmacists’ Recommendations. J. Am. Pharm. Assoc. 2017, 57, S197–S202. [Google Scholar] [CrossRef]
- Ferreri, S.P.; Greco, A.J.; Michaels, N.M.; O’Connor, S.K.; Chater, R.W.; Viera, A.J.; Faruki, H.; McLeod, H.L.; Roederer, M.W. Implementation of a Pharmacogenomics Service in a Community Pharmacy. J. Am. Pharm. Assoc. 2014, 54, 172–180. [Google Scholar] [CrossRef]
- Papastergiou, J.; Quilty, L.C.; Li, W.; Thiruchselvam, T.; Jain, E.; Gove, P.; Mandlsohn, L.; van den Bemt, B.; Pojskic, N. Pharmacogenomics Guided versus Standard Antidepressant Treatment in a Community Pharmacy Setting: A Randomized Controlled Trial. Clin. Transl. Sci. 2021, 14, 1359–1368. [Google Scholar] [CrossRef]
- Hassell, K.; Seston, E.M.; Schafheutle, E.I.; Wagner, A.; Eden, M. Workload in Community Pharmacies in the UK and Its Impact on Patient Safety and Pharmacists’ Well-Being: A Review of the Evidence. Health Soc. Care Community 2011, 19, 561–575. [Google Scholar] [CrossRef]
- Robinson, J. Up to 85% of Community Pharmacies Could Be in Financial Deficit by 2024, Economic Analysis Concludes. Pharm. J. 2020, 305, 7941. [Google Scholar] [CrossRef]
- Wickware, C. Clinical Workload for Community Pharmacists Will Have Nearly Doubled in Five Years, Says PSNC. Pharm. J. 2022, 308, 7957. [Google Scholar] [CrossRef]
- NHS. England NHS Long Term Workforce Plan June 2023. Available online: https://www.england.nhs.uk/publication/nhs-long-term-workforce-plan/ (accessed on 17 October 2023).
- Caudle, K.E.; Gammal, R.S.; Whirl-Carrillo, M.; Hoffman, J.M.; Relling, M.V.; Klein, T.E. Evidence and Resources to Implement Pharmacogenetic Knowledge for Precision Medicine. Am. J. Health-Syst. Pharm. 2016, 73, 1977–1985. [Google Scholar] [CrossRef] [PubMed]
- de Denus, S.; Letarte, N.; Hurlimann, T.; Lambert, J.-P.; Lavoie, A.; Robb, L.; Sheehan, N.L.; Turgeon, J.; Vadnais, B. An Evaluation of Pharmacists’ Expectations towards Pharmacogenomics. Pharmacogenomics 2013, 14, 165–175. [Google Scholar] [CrossRef] [PubMed]
- Bank, P.C.D.; Swen, J.J.; Schaap, R.D.; Klootwijk, D.B.; Baak-Pablo, R.; Guchelaar, H.-J. A Pilot Study of the Implementation of Pharmacogenomic Pharmacist Initiated Pre-Emptive Testing in Primary Care. Eur. J. Hum. Genet. 2019, 27, 1532–1541. [Google Scholar] [CrossRef]
- Mitchell, M.; Stauffenberg, C.; Vernon, V.; Mospan, C.M.; Shipman, A.J.; Rafie, S. Opposition to Pharmacist Contraception Services: Evidence for Rebuttal. Pharmacy 2020, 8, 176. [Google Scholar] [CrossRef]
- The NHS Business Services Authority. NHS Pharmacy Contraception Pilot Service-Initiation of Oral Contraception. Available online: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dispensing-contractors-information/nhs-pharmacy-contraception-pilot-service-tier-2-initiation-oral-contraception (accessed on 17 October 2023).
- Higgs, J.E.; Andrews, J.; Gurwitz, D.; Payne, K.; Newman, W. Pharmacogenetics Education in British Medical Schools. Genom. Med. 2008, 2, 101–105. [Google Scholar] [CrossRef]
- Surofchy, D.; Oh, S.; Galanter, J.; Xiang, P.; Li, M.; Guo, S.; Desai, T.; Gugleilmo, B.J.; Giacomini, K.; Long-Boyle, J.; et al. The Effects of Personal Pharmacogenetic Testing on the Effects of Pharmacy Student Perceptions of Knowledge and Attitudes Towards Precision Medicine. Innov. Pharm. 2017, 8, 1–11. [Google Scholar] [CrossRef]
- Arafah, A.; Rehman, M.U.; Syed, W.; Babelghaith, S.D.; Alwhaibi, A.; Al Arifi, M.N. Knowledge, Attitude and Perception of Pharmacy Students towards Pharmacogenomics and Genetics: An Observational Study from King Saud University. Genes 2022, 13, 269. [Google Scholar] [CrossRef]
Characteristics | Number of Participants (n = 51) n (%) |
---|---|
Age Group | |
23–32 | 25 (49.0) |
33–42 | 12 (23.5) |
43–52 | 10 (19.6) |
53–62 | 4 (7.8) |
63+ | 0 (0) |
Gender | |
Male | 22 (43.1) |
Female | 29 (56.9) |
Other/prefer not to say | 0 |
Number of years in practice | |
<1 | 1 (2.0) |
1–4 | 12 (23.5) |
5–10 | 16 (31.4) |
11–15 | 8 (15.7) |
16–20 | 3 (5.9) |
20+ | 11 (21.6) |
Type of pharmacy | |
Independent pharmacy | 17 (33.3) |
Small pharmacy chain | 15 (29.4) |
Large pharmacy chain | 17 (33.3) |
Small chain and independent pharmacy | 2 (3.9) |
Role within pharmacy | |
Manager | 6 (11.8) |
Responsible pharmacist | 15 (29.4) |
Second pharmacist | 4 (7.8) |
Locum | 19 (37.3) |
Relief | 2 (3.9) |
Mix of the roles above | 5 (9.8) |
Superintendent | 0 (0) |
Drug | Status | % of Pharmacists with Correct Response (n = 49) |
---|---|---|
Abacavir | Current PG testing available | 61% (30/49) |
Carbamazepine | Suitable for future PG testing | 33% (16/49) |
Clopidogrel | Suitable for future PG testing or Current PG testing available | 33% (16/49) 6% (3/49) |
Co-amoxiclav | Neither | 51% (25/49) |
Codeine | Suitable for future PG testing | 17% (8/49) |
Fluorouracil | Current PG testing available | 47% (23/49) |
Sertraline | Suitable for future PG testing | 47% (23/49) |
Simvastatin | Suitable for future PG testing | 45% (22/49) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ghazal, H.; Tahar, A.; Mason, T. Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services? Pharmacy 2023, 11, 170. https://doi.org/10.3390/pharmacy11060170
Ghazal H, Tahar A, Mason T. Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services? Pharmacy. 2023; 11(6):170. https://doi.org/10.3390/pharmacy11060170
Chicago/Turabian StyleGhazal, Heba, Ayaz Tahar, and Thuy Mason. 2023. "Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services?" Pharmacy 11, no. 6: 170. https://doi.org/10.3390/pharmacy11060170